Email
Print
Cyclospora Diagnostic Testing Market - Forecast(2024 - 2030)
Cyclospora Diagnostic Testing Market Overview
The Cyclospora Diagnostic Testing Market size is estimated to reach $1.5 billion by 2028, growing at a CAGR of 7.4% during the forecast period 2023-2028. Cyclospora Diagnostic Testing involves the inspection of stool specimens. Modified acid-fast staining and safranin staining may be applied to oocysts of Cyclospora. Oocysts of Cyclospora in clinical specimens are usually identified by utilizing modified acid-fast stains (cold). The modified safranin method generates more consistent staining of these oocysts. Cyclospora diagnostic testing may be performed in commercial/ private laboratories, hospitals, public health labs and physician offices. The surging technological progress in diagnostic techniques pertaining to cyclosporiasis infections is set to drive the Cyclospora Diagnostic Testing Market. The rising application of basic laboratory tests involving acid-fast staining and safranin staining is set to propel the growth of the Cyclospora Diagnostic Testing Industry during the forecast period 2023-2028. This represents the Cyclospora Diagnostic Testing Industry Outlook.
Cyclospora Diagnostic Testing Market Report Coverage
The “Cyclospora Diagnostic Testing
Market Report - Forecast (2023-2028)” by IndustryARC, covers an
in-depth analysis of the following segments in the Cyclospora Diagnostic Testing Market.
- By Type: Acid-Fast Staining,
Safranin Staining.
- By Application: Commercial Or Private
Laboratories, Hospitals, Public Health Labs and Physician Offices.
- By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America) and Rest Of The World (Middle East and Africa).
Key Takeaways
- Geographically, North America (Cyclospora Diagnostic Testing Market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2023-2028 owing to the existence of strong healthcare infrastructure involving hospitals backing innovations in the North American region.
- Cyclospora Diagnostic Testing Market growth is being driven by scarcity of water which may result in people recycling and consuming unclean water. However, there are no blood tests to diagnose Cyclospora infection whose diagnosis involves the application of acid-fast staining and safranin staining and this is one of the major factors hampering the growth of the Cyclospora Diagnostic Testing Market.
- Cyclospora Diagnostic Testing Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Cyclospora Diagnostic Testing Market report.
Cyclospora Diagnostic Testing Market Segment Analysis - by Type
The Cyclospora Diagnostic Testing Market
based on type can be further segmented into Acid-Fast
Staining and Safranin Staining. The
Safranin Staining Segment
held the largest Cyclospora Diagnostic Testing Market share in 2021. This
growth is owing to the surging application of safranin staining as a diagnostic
test utilized to recognize the existence of Cyclospora in stool samples. The capability
of safranin testing to distinguish Cyclospora from additional enteric pathogens
is further propelling the growth of the Safranin Staining segment.
Furthermore, the Acid-Fast Staining segment
is estimated to grow with the fastest CAGR of 8.4% during the forecast period
2023-2028 owing to the snowballing application of acid-fast staining for the
detection of fast-growing microorganisms like bacteria, fungi and viruses and
its vital significance in the diagnosis of numerous infectious ailments like
cyclosporiasis.
Cyclospora
Diagnostic Testing Market Segment Analysis - by Application
The Cyclospora Diagnostic Testing Market based on the application can be further segmented into Commercial Or Private Laboratories, Hospitals, Public Health Labs and Physician Offices. The Commercial Or Private Laboratories Segment held the largest Cyclospora Diagnostic Testing Market share in 2021. This growth is owing to the increasing application of Commercial/ Private Laboratories for Cyclospora diagnostic testing. There are commercial/private laboratories like Microbac Laboratories which perform Cyclospora testing on request and Microbac is one of the few labs with an accredited technique based on FDA guidance. The burgeoning awareness regarding Cyclospora diagnosis is further propelling the growth of this segment. Furthermore, the Hospitals segment is estimated to grow with the fastest CAGR of 8.8% during the forecast period 2023-2028 owing to the existence of greatly skilled health professionals and progressive diagnostic facilities in hospitals.
Cyclospora Diagnostic Testing Market Segment Analysis - by Geography
North America (Cyclospora
Diagnostic Testing Market) held the largest Cyclospora
Diagnostic Testing Market share with 35% of the overall market in 2021. The growth of this region is
owing to the existence of numerous public health labs and commercial/private
laboratories in the North American region. The technologically progressive
medical products and services are further propelling the growth of the Cyclospora
Diagnostic Testing Industry, thereby contributing to the Cyclospora Diagnostic
Testing Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific
region is estimated to be the region with the fastest CAGR over the
forecast period 2023-2028. This growth is owing to factors like enhanced
healthcare infrastructure in the Asia-Pacific region. The enormous patient pool in India and China is further fuelling the progress of
the Cyclospora Diagnostic Testing Market in the Asia-Pacific region.
Cyclospora Diagnostic Testing Market Drivers
The increasing Predominance of Cyclosporiasis is Projected to Drive the Growth of the Cyclospora Diagnostic Testing Market:
Soaring Progress in Cyclosporiasis Diagnosis is Expected to Boost the Growth of the Cyclospora Diagnostic Testing industry:
Cyclospora diagnosis involves detection in the stool. There are different techniques of oocyte morphology detection. These include web smears, staining tests, fluorescence tests, flow cytometry, serological tests, molecular detection as well as case-linking and tracking. Web smears and traditional microscopy techniques have been extensively utilized to detect C. cayetanensis oocysts in clinical stool samples (Ortega and Sanchez, 2010). Cyclospora oocysts in stool are effortlessly recognized as spherical and refractile entities that are 8–10 m in size and possess a central morula. The soaring progress in cyclosporiasis diagnosis is therefore driving the growth of the Cyclospora Diagnostic Testing Industry, thereby contributing to the Cyclospora Diagnostic Testing Industry Outlook during the forecast period 2023-2028.
Cyclospora Diagnostic Testing Market Challenge
Diagnosis of Cyclospora Being Difficult is Hampering the Growth of the Cyclospora Diagnostic Testing Market:
Diagnosis of Cyclospora infection may be hard. Recognition of Cyclospora needs special laboratory tests that are not normal and need to be particularly requested. Patients will be questioned to supply at least 3 stool samples over numerous days. Then, microbiologists analyze the samples and look for Cyclospora oocysts, which are non-infectious immature parasites that are cast off periodically in stools. The laboratory diagnosis of newly identified infectious agents, like Cyclospora cayetanensis, is periodically problematic owing to the lack of availability of suitable diagnostic techniques and algorithms. These issues are thus hampering the growth of the Cyclospora Diagnostic Testing Market.
Cyclospora Diagnostic Testing Industry Outlook
Generation of cyclosporiasis diagnostic kits, technological advancements and R&D activities in diagnostic techniques and key strategies adopted by players in the Cyclospora Diagnostic Testing Market. The top 10 companies in the Cyclospora Diagnostic Testing Market are:
- Thermo Fisher Scientific Inc.
- Beckman Coulter Inc.
- bioMerieux, Inc.
- CEPHEID
- Diamedix Corporation
- Hologic, Inc.
- Nanogen, Inc.
- Ortho Clinical Diagnostics (a Johnson & Johnson company)
- DiaSorin S.p.A.
- Roche Diagnostics (a division of Hoffmann-La Roche)
Recent Developments
- In February 2022, Thermo Fisher Scientific Inc. declared the introduction of a novel accelerated environmental test. This is to assist in the combat against COVID-19. The Renvo Rapid PCR Test is planned for environmental surveillance only.
- In February 2021, Thermo Fisher Scientific Inc. declared that it has finished its formerly declared acquisition of Mesa Biotech, Inc. Mesa Biotech has established the Accula System. The platform permits accelerated greatly precise testing.
- In March 2020, Thermo Fisher Scientific Inc. declared that the U.S. Food And Drug Administration issued an emergency use authorization for its diagnostic test. It can be utilized instantly by CLIA high complexity labs in the U.S. Nucleic acid and may be detected from SARS-CoV-2.
Relevant Reports
Report Code: HCR 0285
Report Code: HCR 0945
Report Code: HCR 0021
For more Lifesciences and Healthcare Market reports, please click here